Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2017

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions

Clear Cell Renal Cell CarcinomaMetastatic Kidney CarcinomaStage III Renal Cell Cancer AJCC v7Stage IV Renal Cell Cancer AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Sitravatinib

Given PO

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03015740 - Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter